HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS

被引：0
作者：
Burne, R. [1 ]
Balu, S. [2 ]
Guerin, A. [1 ]
Liang, Y. [1 ]
Schloessmann, R. [3 ]
Bungay, R. [1 ]
Paul, M. L. [2 ]
机构：
[1] Anal Grp Inc, Montreal, PQ, Canada
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Anal Grp Inc, Chicago, IL USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN120
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [1] HR+/HER2-metastatic Breast Cancer Increasing Data Density of CDK4/6 Inhibitors
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (09) : 485 - 485
  • [2] Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
    Abdallah, H. M. A.
    Owoseni, Y. I.
    Sultan, A.
    Ahmed, S.
    Wood, J.
    Varadhan, B.
    Ayodele, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S370
  • [3] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [4] How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
    Cogliati, Viola
    Capici, Serena
    Pepe, Francesca Fulvia
    di Mauro, Pierluigi
    Riva, Francesca
    Cicchiello, Federica
    Maggioni, Claudia
    Cordani, Nicoletta
    Cerrito, Maria Grazia
    Cazzaniga, Marina Elena
    LIFE-BASEL, 2022, 12 (03):
  • [5] Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Moiso, Enrico
    Ferraro, Emanuela
    Cabel, Luc
    Safonov, Anton
    Ahmed, Mehnaj
    An, Julia Ah-Reum
    Jhaveri, Komal L.
    Norton, Larry
    Robson, Mark E.
    Modi, Shanu
    Chandarlapaty, Sarat
    Razavi, Pedram
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
  • [7] Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer
    Weiss, Jennifer
    Afghahi, Anosheh
    Shagisultanova, Elena
    Diamond, Jennifer R.
    ONCOLOGY-NEW YORK, 2018, 32 (10): : 513 - 515
  • [8] Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2-Metastatic Breast Cancer
    Goyal, Ravi K.
    Candrilli, Sean D.
    Abughosh, Susan
    Chen, Hua
    Holmes, Holly M.
    Johnson, Michael L.
    CANCERS, 2024, 16 (12)
  • [9] Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2-Metastatic Breast Cancer in Postmenopausal Women in the USA
    Masurkar, Prajakta P.
    Damgacioglu, Haluk
    Deshmukh, Ashish A.
    Trivedi, Meghana V.
    PHARMACOECONOMICS, 2023, 41 (06) : 709 - 718
  • [10] Treatment patterns for young women with HR+/HER2-metastatic breast cancer in the United States in the era of CDK 4/6 inhibitors
    Burstein, Harold J.
    Mayer, Erica L.
    DeMichele, Angela
    Harnett, James
    Mardekian, Jack
    McRoy, Lynn
    Bartlett, Cynthia Huang
    Koehler, Maria
    Rimawi, Mothaffar Fahed
    CANCER RESEARCH, 2018, 78 (04)
12345